Author: Hopstem Biotechnology Inc.

Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications

July 29, 2026
Hopstem hNPC01 Cell Injection Earns FDA RMAT Designation for Chronic Stroke Therapy

June 3, 2026

Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications